Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.

Koji SasakiElias J JabbourFarhad RavandiNicholas J ShortDeborah A ThomasGuillermo Garcia-ManeroNaval G DaverTapan M KadiaMarina Y KonoplevaNitin JainGhayas C IssaVicki JeanisHaim G MooreRebecca S GarrisNaveen PemmarajuJorge E CortesSusan M O'BrienHagop M Kantarjian

Published in: Cancer (2016)

The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016;122:3650-6. © 2016 American Cancer Society.

Keyphrases

acute lymphoblastic leukemia
chronic myeloid leukemia
papillary thyroid
squamous cell
allogeneic hematopoietic stem cell transplantation
acute myeloid leukemia
copy number
dna methylation
young adults
genome wide
data analysis